DGIdb - TESEVATINIB Drug Record

TESEVATINIB chembl:CHEMBL3544983 Antineoplastic

Alternate Names:

EXEL-7647
XL-647
KD-019
KD019
XL647
TESEVATINIB
KD-020

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent

(3 More Sources)

Publications:

Pietanza et al., 2012, Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer., J Thorac Oncol
Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.
Trowe et al., 2008, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation., Clin. Cancer Res.

TESEVATINIB EPHB4

Interaction Score: 11.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Ephrin type-B receptor 4 inhibitor

Trial Name XL647

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD
TESEVATINIB PTK2B

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TESEVATINIB ERBB2

Interaction Score: 0.42

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

Direct Interaction yes

Evidence Type Actionable

PMIDs:
19718025 18413839

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions
TESEVATINIB EGFR

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

Direct Interaction yes

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
22722787

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions
TESEVATINIB FLT1

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial
TESEVATINIB FLT4

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial
TESEVATINIB KDR

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

MyCancerGenome: XL647
- Version: 20-Jun-2017
Alternate Names:

XL647 Development Name

KD019 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: XL647
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

JAX-CKB: XL647

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Pietanza et al., 2012, Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer., J Thorac Oncol

Trowe et al., 2008, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation., Clin. Cancer Res.

Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.

TALC: XL647
- Version: 12-May-2016
Alternate Names:

XL647 Primary Drug Name

XL647 Drug Synonym

Drug Info:

Publications:
TTD: KD019
- Version: 2020.06.01
Alternate Names:

D06WRF TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3544983
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3544983
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Ephrin type-B receptor 4 inhibitor
Trial Name	XL647

Mechanism of Interaction	Receptor protein-tyrosine kinase erbB-2 inhibitor
Direct Interaction	yes
Evidence Type	Actionable

Mechanism of Interaction	Epidermal growth factor receptor erbB1 inhibitor
Direct Interaction	yes
Indication/Tumor Type	non-small cell lung carcinoma

Trial Name	XL647
Novel drug target	Established target

Trial Name	XL647
Novel drug target	Established target

Notes
Trial Name	XL647
Novel drug target	Established target

TESEVATINIB Drug Record

TESEVATINIB chembl:CHEMBL3544983 Antineoplastic

Alternate Names:

Drug Info:

Publications:

TESEVATINIB EPHB4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Ephrin type-B receptor 4 inhibitor Trial Name XL647

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

TESEVATINIB PTK2B

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TESEVATINIB ERBB2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor Direct Interaction yes Evidence Type Actionable

PMIDs: 19718025 18413839

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

TESEVATINIB EGFR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor Direct Interaction yes Indication/Tumor Type non-small cell lung carcinoma

PMIDs: 22722787

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

TESEVATINIB FLT1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name XL647 Novel drug target Established target

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial

TESEVATINIB FLT4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name XL647 Novel drug target Established target

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial

TESEVATINIB KDR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name XL647 Novel drug target Established target

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

MyCancerGenome: XL647

Alternate Names: XL647 Development Name KD019 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: XL647

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

JAX-CKB: XL647

Alternate Names:

Drug Info:

TALC: XL647

Alternate Names: XL647 Primary Drug Name XL647 Drug Synonym

Drug Info:

Publications:

TTD: KD019

Alternate Names: D06WRF TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3544983

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL3544983

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Ephrin type-B receptor 4 inhibitor

Trial Name XL647

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

Direct Interaction yes

Evidence Type Actionable

PMIDs:
19718025 18413839

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

Direct Interaction yes

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
22722787

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name XL647

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Alternate Names:

XL647 Development Name

KD019 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Alternate Names:

XL647 Primary Drug Name

XL647 Drug Synonym

Alternate Names:

D06WRF TTD Drug ID